Amaza Reitmeier is the Chief Executive Officer and a member of the Board of Directors at Pharaoh Neuro, where she leads the company’s mission to transform neurocritical care through next‑generation technology. She brings more than two decades of global leadership experience in medical devices, neuroscience, and digital innovation.
Before joining Pharaoh Neuro, Reitmeier spent over 20 years at Medtronic, where she held senior executive roles spanning business leadership, commercial strategy, operations, and therapy innovation. Throughout her tenure, she successfully led multiple high‑growth businesses, advanced groundbreaking neurotherapies, and drove cross‑functional teams in bringing complex technologies from concept to commercial scale.
Reitmeier’s leadership has been recognized across the industry, including her role in championing adaptive deep brain stimulation (aDBS)—a breakthrough technology honored as TIME Magazine’s 2025 Healthcare Innovation of the Year. Her track record reflects a commitment to advancing patient outcomes, fostering high‑performing teams, and accelerating innovation at the intersection of neuroscience and technology.
As CEO of Pharaoh Neuro, she brings this breadth of expertise to guide the company through its next phase of growth and scientific impact.